Today: 19 July 2026
Browse Category

NYSE:ABBV 14 December 2025 - 2 January 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Inc. heads into the weekend with Wall Street shut and year-end positioning in full swing, after a quiet, post-holiday session on Friday left major U.S. indexes essentially unchanged. In thin trading, investors continue to weigh two competing narratives: a strong 2025 for equities and the seasonally bullish “Santa Claus rally” window — versus the reality that year-end liquidity can amplify moves on any surprise headline. Reuters
27 December 2025
···
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie Inc. stock traded mostly steady to slightly higher on Tuesday, Dec. 23, 2025, as investors balanced a holiday-shortened trading week with a fresh burst of company-specific pipeline headlines and ongoing debate about U.S. drug-pricing policy. As of Tuesday afternoon, ABBV changed hands around $228.62, up about 0.31% on the day, after trading in a $227.88–$230.77 range.
23 December 2025
·
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Inc. heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through “most‑favored‑nation” style commitments and new direct-to-consumer programs.
22 December 2025
···
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing forces: strong underlying fundamentals and a renewed policy overhang as Washington accelerates its latest push to align U.S. drug prices with lower international benchmarks.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals and policy/pipeline debates that could shape sentiment into 2026.
21 December 2025
··
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session at $226.82, up 1.80%, while trading volume surged well above its recent average — a sign that investors were repositioning into large-cap pharma after a rapid sequence of Washington announcements. MarketWatch
20 December 2025
·
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie Inc. heads into the Monday, December 15, 2025 US market open with a familiar “big pharma” setup—steady cash returns, blockbuster execution, and a pipeline that’s increasingly being treated as a source of upside rather than a safety net. Shares last traded around $223.32, slipping modestly at Friday’s close as broader markets softened, but ABBV remains one of the stronger large-cap pharma performers in 2025. MarketWatch
14 December 2025
··
1 2 3 4 5 6
Go toTop